POST
FUZZYWUZZY
Title: COVID-19 vaccine
Date: 01/11/2020 10:41:21
ID: 983355029
Fulltext: <td class="diff-addedline"><div>Temporarily paused on October 13 2020 due to an unexplained illness in a participant.</div></td>
Changed Text: <td class="diff-addedline"><div>Temporarily paused on October 13 2020 due to an unexplained illness in a participant.&lt;ref&gt;{{Cite we|title=Johnson &amp; Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials|url=https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials}}&lt;/ref&gt;</div></td>
Printed Text: <td class="diff-addedline"><div>Temporarily paused on October 13 2020 due to an unexplained illness in a participant.</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986506300&oldid=983355029
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=983355029&oldid=983352748
Fuzzy: Temporarily paused on 13 October 2020, due to an unexplained illness in a participant.[120][121][122][123] Johnson & Johnson announced, on 23 October, that they are preparing to resume the trial in the US.[124][125][88]



POST
FUZZYWUZZY
Title: COVID-19 vaccine
Date: 01/11/2020 10:41:22
ID: 984530064
Fulltext: <td class="diff-addedline"><div>Strategies are being considered for fast-tracking the licensing of a vaccine against COVID‑19, especially by compressing (to a few months) the usually lengthy duration of Phase{{nbsp}}II–III trials (typically many years). [[Human challenge study|Challenge studies]] have been implemented previously for diseases less deadly than COVID‑19 infection, such as common influenza, [[typhoid fever]], [[cholera]], and [[malaria]].<ins class="diffchange diffchange-inline"> Once an infection dose of COVID-19 is identified, two or more of the candidate COVID-19 vaccines will be tested for effectiveness in preventing infection. </ins></div></td>
Changed Text: <td class="diff-addedline"><div>Strategies are being considered for fast-tracking the licensing of a vaccine against COVID‑19, especially by compressing (to a few months) the usually lengthy duration of Phase{{nbsp}}II–III trials (typically many years).&lt;ref name="eyal"&gt;{{Cite journal|last1=Eyal|first1=Nir|last2=Lipsitch|first2=Marc|last3=Smith|first3=Peter G.|title=Human challenge studies to accelerate coronavirus vaccine licensure|url=https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|journal=The Journal of Infectious Diseases|doi=10.1093/infdis/jiaa152|date=31 March 2020|volume=221|issue=11|pages=1752–56|pmid=32232474|pmc=7184325|name-list-style=vanc|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200424095527/https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|archive-date=24 April 2020|url-status=live}}&lt;/ref&gt;&lt;ref name="callaway"&gt;{{Cite journal|vauthors=Callaway E|date=April 2020|title=Should scientists infect healthy people with the coronavirus to test vaccines?|url=https://www.nature.com/articles/d41586-020-00927-3|journal=Nature|volume=580|issue=7801|page=17|doi=10.1038/d41586-020-00927-3|pmid=32218549|bibcode=2020Natur.580...17C|doi-access=free|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200414035045/https://www.nature.com/articles/d41586-020-00927-3|archive-date=14 April 2020|url-status=live}}&lt;/ref&gt;&lt;ref name="boodman"&gt;{{Cite web|url=https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/|title=Coronavirus vaccine clinical trial starting without usual animal data|publisher=STAT|first=Eric | last=Boodman |date=13 March 2020|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200417060301/https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/|archive-date=17 April 2020|url-status=live| name-list-style=vanc }}&lt;/ref&gt; [[Human challenge study|Challenge studies]] have been implemented previously for diseases less deadly than COVID‑19 infection, such as common influenza, [[typhoid fever]], [[cholera]], and [[malaria]].&lt;ref name=callaway/&gt;&lt;ref name=cohen/&gt; Following preliminary proof of safety and efficacy of a candidate vaccine in laboratory animals and healthy humans, controlled challenge studies might be implemented to bypass typical Phase{{nbsp}}III research, providing an accelerated path to license a COVID‑19 vaccine.&lt;ref name="eyal" /&gt;&lt;ref name="cohen"&gt;{{Cite journal|url=https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some|title=Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn|last=Cohen|first=Jon|date=31 March 2020|journal=Science|doi=10.1126/science.abc0006|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200414031310/https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some|archive-date=14 April 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;&lt;ref name=callaway/&gt;<ins class="diffchange diffchange-inline"> Beginning in January 2021, dozens of young adult volunteers will be deliberately infected with COVID-19 in a challenge trial conducted in a [[London, England|London]] hospital under management by the UK government COVID-19 Vaccine Taskforce.&lt;ref name="call-challenge"&gt;{{cite journal |author1=Ewen Callaway |title=Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials |journal=Nature |date=20 October 2020 |doi=10.1038/d41586-020-02821-4 |url=https://www.nature.com/articles/d41586-020-02821-4}}&lt;/ref&gt; Once an infection dose of COVID-19 is identified, two or more of the candidate COVID-19 vaccines will be tested for effectiveness in preventing infection.&lt;ref name=call-challenge/&gt; </ins></div></td>
Printed Text: <td class="diff-addedline"><div>Strategies are being considered for fast-tracking the licensing of a vaccine against COVID‑19, especially by compressing (to a few months) the usually lengthy duration of Phase{{nbsp}}II–III trials (typically many years). Challenge studies have been implemented previously for diseases less deadly than COVID‑19 infection, such as common influenza, typhoid fever, cholera, and malaria.<ins class="diffchange diffchange-inline"> Once an infection dose of COVID-19 is identified, two or more of the candidate COVID-19 vaccines will be tested for effectiveness in preventing infection. </ins></div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986506300&oldid=984530064
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=984530064&oldid=984528753
Fuzzy: COVID-19 vaccine


POST
FUZZYWUZZY
Title: COVID-19 vaccine
Date: 01/11/2020 10:41:23
ID: 985479328
Fulltext: <td class="diff-addedline"><div>Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other<ins class="diffchange diffchange-inline"> affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.</ins></div></td>
Changed Text: <td class="diff-addedline"><div>Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other<ins class="diffchange diffchange-inline"> affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.&lt;ref name=who-vacc/&gt;</ins></div></td>
Printed Text: <td class="diff-addedline"><div>Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other<ins class="diffchange diffchange-inline"> affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.</ins></div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986506300&oldid=985479328
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985479328&oldid=985478714
Fuzzy: 
More



POST
FUZZYWUZZY
Title: COVID-19 vaccine
Date: 01/11/2020 10:41:24
ID: 985479328
Fulltext: <td class="diff-addedline"><div>In October 2020, the Australian [[Therapeutic Goods Administration]] (TGA) granted provisional determinations to AstraZeneca Pty Ltd in relation to its COVID-19 vaccine, ChAd0x1-S [recombinant] and to Pfizer Australia Pty Ltd in relation to its COVID-19 vaccine, BNT162b2 [mRNA].</div></td>
Changed Text: <td class="diff-addedline"><div>In October 2020, the Australian [[Therapeutic Goods Administration]] (TGA) granted provisional determinations to AstraZeneca Pty Ltd in relation to its COVID-19 vaccine, ChAd0x1-S [recombinant] and to Pfizer Australia Pty Ltd in relation to its COVID-19 vaccine, BNT162b2 [mRNA].&lt;ref&gt;{{cite web | title=TGA grants provisional determination for COVID-19 vaccine | website=[[Therapeutic Goods Administration]] (TGA) | date=9 October 2020 | url=https://www.tga.gov.au/tga-grants-provisional-determination-covid-19-vaccine | access-date=25 October 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite web | title=TGA grants second provisional determination for a COVID-19 vaccine | website=[[Therapeutic Goods Administration]] (TGA) | date=14 October 2020 | url=https://www.tga.gov.au/tga-grants-second-provisional-determination-covid-19-vaccine | access-date=25 October 2020}}&lt;/ref&gt;</div></td>
Printed Text: <td class="diff-addedline"><div>In October 2020, the Australian Therapeutic Goods Administration (TGA) granted provisional determinations to AstraZeneca Pty Ltd in relation to its COVID-19 vaccine, ChAd0x1-S [recombinant] and to Pfizer Australia Pty Ltd in relation to its COVID-19 vaccine, BNT162b2 [mRNA].</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986506300&oldid=985479328
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985479328&oldid=985478714
Fuzzy: COVID-19 vaccine


POST
FUZZYWUZZY
Title: COVID-19 vaccine
Date: 01/11/2020 10:41:25
ID: 985484532
Fulltext: <td class="diff-addedline"><div>Temporarily paused on 13 October 2020, due to an unexplained illness in a participant. Johnson &amp; Johnson announced, on 23 October, that they are preparing to resume the trial in the US.</div></td>
Changed Text: <td class="diff-addedline"><div>Temporarily paused on 13 October 2020, due to an unexplained illness in a participant.&lt;ref&gt;{{cite news | title=Johnson &amp; Johnson pauses its coronavirus vaccine trial because of a volunteer's 'unexplained illness.' | website=[[The New York Times]] | date=13 October 2020 | url=https://www.nytimes.com/2020/10/12/world/johnson-johnson-pauses-its-coronavirus-vaccine-trial-because-of-a-volunteers-unexplained-illness.html | access-date=25 October 2020 | authors=Virginia Hughes, Katie Thomas, Carl Zimmer, Katherine J. Wu}}&lt;/ref&gt;&lt;ref&gt;{{cite news | url=https://www.wsj.com/articles/johnson-johnson-pauses-covid-19-vaccine-trials-due-to-sick-subject-11602555101 | title=Johnson &amp; Johnson Pauses Covid-19 Vaccine Trials Due to Sick Subject | work=[[The Wall Street Journal]] | first1=Peter | last1=Loftus | date=13 October 2020 | name-list-style=vanc }}&lt;/ref&gt;&lt;ref&gt;{{cite web|title=Johnson &amp; Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials|url=https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials}}&lt;/ref&gt;&lt;ref&gt;{{cite news | url=https://www.washingtonpost.com/health/2020/10/13/covid-vaccine-trial-pause/ | title=Johnson &amp; Johnson, Eli Lilly pause covid-19 trials for possible safety issues | work=[[The Washington Post]] | date=13 October 2020 | | first=Carolyn Y. | last=Johnson | name-list-style=vanc }}&lt;/ref&gt; Johnson &amp; Johnson announced, on 23 October, that they are preparing to resume the trial in the US.&lt;ref&gt;{{cite news | url=https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923 | title=Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&amp;J Resuming | work=[[The Wall Street Journal]] | first1=Thomas M. | last1=Burton | first2=Peter | last2=Loftus | date=23 October 2020 | name-list-style=vanc }}&lt;/ref&gt;&lt;ref&gt;{{cite news | url=https://www.washingtonpost.com/health/2020/10/23/jj-vaccine-trial-to-resume/ | title=Johnson &amp; Johnson, AstraZeneca coronavirus vaccine trials set to resume | work=[[The Washington Post]] | date=24 October 2020 | | first=Carolyn Y. | last=Johnson | name-list-style=vanc }}&lt;/ref&gt;&lt;ref name="NYT 20201023"&gt;{{cite news | title=Two Companies Restart Virus Trials in U.S. After Safety Pauses | website=[[The New York Times]] | date=23 October 2020 | url=https://www.nytimes.com/2020/10/23/health/covid-vaccine-astrazeneca-johnson-and-johnson.html | access-date=25 October 2020 | authors=Katherine J. Wu, Carl Zimmer, Sharon LaFraniere, Noah Weiland }}&lt;/ref&gt;</div></td>
Printed Text: <td class="diff-addedline"><div>Temporarily paused on 13 October 2020, due to an unexplained illness in a participant. Johnson &amp; Johnson announced, on 23 October, that they are preparing to resume the trial in the US.</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986506300&oldid=985484532
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985484532&oldid=985480641
Fuzzy: Temporarily paused on 13 October 2020, due to an unexplained illness in a participant.[120][121][122][123] Johnson & Johnson announced, on 23 October, that they are preparing to resume the trial in the US.[124][125][88]



POST
FUZZYWUZZY
Title: COVID-19 vaccine
Date: 01/11/2020 10:41:25
ID: 986505776
Fulltext: <td class="diff-addedline"><div>In October 2020, it was announced that Moderna's [[mRNA vaccine]] will be manufactured in [[Visp]], [[Switzerland]] by its partner [[Lonza Group]], which is starting to produce the first doses in December of 2020.  The newly built 2,000-square-metre facility will ramp up production to 300 million doses annually. The ingredient will be shipped frozen at -70° C to [[Spain]]’s Laboratorios Farmacéuticos Rovi SA for the final stage of manufacture. A number of countries, including [[Switzerland]] and [[Japan]] have secured contractual access to this vaccine once it is commercially available. Lonza’s site in [[Portsmouth]], [[New Hampshire]], aims to start making vaccine ingredients exclusively for the U.S. as early as November.</div></td>
Changed Text: <td class="diff-addedline"><div>In October 2020, it was announced that Moderna's [[mRNA vaccine]] will be manufactured in [[Visp]], [[Switzerland]] by its partner [[Lonza Group]], which is starting to produce the first doses in December of 2020.  The newly built 2,000-square-metre facility will ramp up production to 300 million doses annually. The ingredient will be shipped frozen at -70° C to [[Spain]]’s Laboratorios Farmacéuticos Rovi SA for the final stage of manufacture. A number of countries, including [[Switzerland]] and [[Japan]] have secured contractual access to this vaccine once it is commercially available. Lonza’s site in [[Portsmouth]], [[New Hampshire]], aims to start making vaccine ingredients exclusively for the U.S. as early as November.&lt;ref&gt; [https://www.swissinfo.ch/eng/sci-tech/swiss-factory-rushes-to-prepare-for-moderna-covid-19-vaccine/46081656?utm_campaign=swi-rss&amp;utm_content=o&amp;utm_medium=rss&amp;utm_source=apln "Swiss factory rushes to prepare for Moderna Covid-19 vaccine"]. ''SWI swissinfo.ch''. Retrieved November 1st 2020.&lt;/ref&gt;</div></td>
Printed Text: <td class="diff-addedline"><div>In October 2020, it was announced that Moderna's mRNA vaccine will be manufactured in Visp, Switzerland by its partner Lonza Group, which is starting to produce the first doses in December of 2020.  The newly built 2,000-square-metre facility will ramp up production to 300 million doses annually. The ingredient will be shipped frozen at -70° C to Spain’s Laboratorios Farmacéuticos Rovi SA for the final stage of manufacture. A number of countries, including Switzerland and Japan have secured contractual access to this vaccine once it is commercially available. Lonza’s site in Portsmouth, New Hampshire, aims to start making vaccine ingredients exclusively for the U.S. as early as November.</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986506300&oldid=986505776
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=986505776&oldid=986263229
Fuzzy: In October 2020, it was announced that Moderna's mRNA vaccine will be manufactured in Visp, Switzerland by its partner Lonza Group, which is starting to produce the first doses in December of 2020.  The newly built 2,000-square-metre facility will ramp up production to 300 million doses annually. The ingredient will be shipped frozen at -70° C to Spain’s Laboratorios Farmacéuticos Rovi SA for the final stage of manufacture. A number of countries, including Switzerland and Japan have secured contractual access to this vaccine once it is commercially available. Lonza’s site in Portsmouth, New Hampshire, aims to start making vaccine ingredients exclusively for the U.S. as early as November.[250]



